Sarepta Therapeutics to Share New Clinical Data and Integrated Analysis for SRP-9001, its Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy on July 6, 2022 at 8:30am ET

Rhea-AI Summary

Sarepta Therapeutics (NASDAQ:SRPT) will host a webcast on July 6, 2022, to present new functional data from the clinical trials of SRP-9001, an investigational gene therapy for Duchenne muscular dystrophy (DMD). The company will share an integrated analysis of one-year data across three studies (101, 102, and 103) involving participants who received the target dose of SRP-9001, comparing results to an external control group. The event will be accessible via their investor relations website.

Positive

• Upcoming webcast to present new functional data for SRP-9001.
• Integrated analysis of one-year data from three studies may validate the therapy's efficacy.

Negative

• None.

CAMBRIDGE, Mass., July 05, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that on Wednesday, July 6, 2022 at 8:30am Eastern Time, the Company will host a webcast and conference call to share new functional data across multiple studies from the clinical development program for SRP-9001 (delandistrogene moxeparvovec) for the treatment of Duchenne muscular dystrophy. The Company also plans to present an integrated analysis of one-year functional data from Studies 101, 102 and 103 for all participants that received the target dose of SRP-9001 compared to a propensity-weighted external control group. SRP-9001 is an investigational gene therapy for Duchenne being developed in partnership with Roche.

The presentation will be webcast live under the investor relations section of Sarepta's website at https://investorrelations.sarepta.com/events-presentations and following the event a replay will be archived there for one year. This event will include a slide presentation and participants are encouraged to view the event via the webcast link. Interested parties may also participate by phone by registering using this online form. After registering for dial-in details, all phone participants will receive an auto-generated e-mail containing a link to the dial-in number along with a personal PIN number to use to access the event by phone.

About Sarepta Therapeutics
Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold leadership positions in Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs), and we currently have more than 40 programs in various stages of development. Our vast pipeline is driven by our multi-platform Precision Genetic Medicine Engine in gene therapy, RNA, and gene editing. For more information, please visit www.sarepta.com or follow us on Twitter, LinkedIn, Instagram and Facebook.

Internet Posting of Information
We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.

Source: Sarepta Therapeutics, Inc.

Investor Contact:
Ian Estepan, 617-274-4052
iestepan@sarepta.com

Media Contact:
Tracy Sorrentino, 617-301-8566
tsorrentino@sarepta.com 

FAQ

What is the purpose of the webcast by Sarepta Therapeutics on SRP-9001?

The webcast aims to share new functional data from the clinical development program for SRP-9001, an investigational gene therapy for Duchenne muscular dystrophy.

What are the key studies involved in the SRP-9001 data presentation?

The key studies are Studies 101, 102, and 103, which focus on one-year functional data for participants receiving the target dose of SRP-9001.

How does SRP-9001 compare to existing treatments for Duchenne muscular dystrophy?

SRP-9001 is positioned as a novel investigational gene therapy, expected to provide improved outcomes compared to current available treatments.

What is the market impact of the new data on SRP-9001?

Positive data could strengthen Sarepta's position in the market for Duchenne muscular dystrophy treatments, potentially influencing investor sentiment and stock performance.